Aspirin Reduce Cancer Deaths

Eating on the long-term low-dose aspirin every day, the risk of dying from various forms of cancer.

Recent research in England found these glad tidings. Besides effective pain relief, pain and inflammation, the benefits of aspirin continues to grow with the relentless researchers.

Recent research shows that prolonged use of low dose aspirin each day can significantly reduce the risk of death from various cancers. In particular, the team of British researchers have found evidence that low-dose aspirin (approximately 75 mg) orally every day for at least five years, the mortality rate of patients with cancer should be reduced from 10 percent to 60 percent, depending on the type of cancer.

These findings come from an in-depth analysis of eight studies involving more than 25,500 patients, which was originally performed to evaluate the potential of a low-dose aspirin test in the treatment of patients with cardiovascular disease. These observations follow a previous study conducted by a team of the same study, reported in October that the long-term treatment of low-dose aspirin appears to reduce the risk of death from colorectal cancer or colorectal cancer reduced to one third.

"These findings provide new evidence in humans that aspirin deaths of some common types of cancer decreases," said research team.

But the study lead author, Professor Peter Rothwell from the John Radcliffe Hospital and the University of Oxford, United Kingdom, emphasized that the results of this study does not mean that all adults should start taking aspirin. "This (aspirin) showed many new benefits, which previously had never been in a recommendation of medical guidelines," he said as quoted by healthday.com page.

He noted, had previously warned that the guidelines on a healthy middle-aged, a little bleeding risk in the stomach when taking aspirin. Yet it is a balanced benefits in the prevention of stroke and heart attack.

"But the reduction in deaths from a number of common cancers that many people now under wraps," said Rothwell.

Rothwell and colleagues published their findings in the journal The Lancet online edition on Tuesday (7 / 12). The study included the review of the past when this was done for an average period of four to eight years.

Patients (some of which have been given treatment with low dose aspirin, while others do not) is to expire 20 years later be verified. The authors have determined when the investigation continues, the risk of total cancer mortality be reduced by 21 percent among those taking low-dose aspirin.

However, long-term benefits in some specific forms of cancer starts to get results five years after the study ended show. Since the current five years study, gastrointestinal cancer deaths decreased by 54 percent in patients who eat a low-dose aspirin.

The protective effect of low dose aspirin on the stomach and intestinal cancer mortality was not seen until 10 years of running the study. As for prostate cancer, the benefits first appeared after 15 years of running the study.

Meanwhile, 20 years after the start of the program of low-dose aspirin, the risk of death fell by 10 percent in patients with prostate cancer, 30 percent in patients with lung cancer (although only those who develop adenocarcinoma, the type of cancer usually affects smokers), 40 percent in patients with colorectal cancer, and 60 percent in patients with esophageal cancer. The researchers note, the potential effect of aspirin intake on pancreatic cancer, stomach cancer, and brains cancer is the most difficult to measure because the death rate of people with the disease are relatively small.

They also found that high doses of aspirin does not appear to benefit from a better protection against the disease. History of gender or smoking habits, the consequences of the use of low dose aspirin effect, while the age factor is very influential. 20-year risk of death fell by more dramatic among older patients.

Researchers have also warned that further studies are needed to a "proof of principle" to build. Therefore, the researchers suggest that people who start with the long-term low-dose aspirin for the treatment of cancer in their 40s and 50s, it is possible to get the greatest benefit.

Dr. Alan Arslan, an assistant professor in the department of obstetrics, gynecology and Langon environmental medicine at NYU Medical Center in New York City, USA, described the results "very important". "(It) is the largest study which showed that people who take aspirin for long periods have a lower risk of death from cancer, especially gastrointestinal cancer," he said.

"The message can be taken by patients is that if someone has a low-or standard-dose aspirin, perhaps putting them at a reduced risk of death from cancer used," Arslan added.

"But if someone has not yet started to take aspirin, they should consult with your doctor before you begin to eat because the drug has a risk of side effects, including bleeding and stroke," he said.